ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2015 American Transplant Congress

    Six Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Mismatched Living Donor Renal Transplant Recipients

    J. Leventhal, M. Abecassis, L. Gallon, J. Galvin, J. Mehta, K. Ravindra, D. Tollerud, M. Elliott, S. Ildstad.

    Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL; Duke University, Durham, NC; Institute for Cellular Therapeutics, University of Louisville, Louisville, KY; Regenerex, LLC, Louisville, KY.

    27 subjects have been transplanted in a phase 2 protocol (IDE 13947) based upon tolerogenic CD8+/TCR- facilitating cells (FCRx) and 200 cGy TBI-based nonmyeloablative conditioning…
  • 2015 American Transplant Congress

    Economic Analysis of Kidney Transplant Tolerance: The Holy Grail Is Less Costly

    N. Elias, S. Shao, T. Gift, B. Patel, A. Cosimi, T. Kawai.

    Transplant Surgery, Massachusetts General Hospital, Boston, MA.

    Introduction: Kidney transplantation (KTx), although expensive, is a more cost effective treatment for end-stage renal disease (ESRD) than dialysis, and provides better long term survival…
  • 2015 American Transplant Congress

    An Economic Analysis of Tolerance Induction for Two-Haplotype Match Kidney Living Donor Transplant Recipients

    K. Erickson,1 W. Winkelmayer,2 R. Lowsky,1 J. Scandling,1 S. Strober.1

    1Medicine, Stanford University, Palo Alto, CA; 2Medicine, Baylor College of Medicine, Houston, TX.

    Purpose:Tolerance induction is a novel therapy that enables some living donor kidney transplant recipients (LDKTR) to safely discontinue immunosuppressive (IS) therapy. We examine whether tolerance…
  • 2015 American Transplant Congress

    Identifying the “Operational Tolerant” Pediatric Liver Transplant Recipient by Cytometry by Time-of-Flight

    A. Lau,1,2 M. Vitalone,1 K. Haas,3 T. Shawler,1 C. Esquivel,1 O. Martinez,1 R. Castillo,3 S. Krams.1

    1Surgery, Division of Abdominal Transplantation, Stanford University, Stanford, CA; 2Pediatrics, Div. Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco, San Francisco, CA; 3Pediatrics, Div. Gastroenterology, Hepatology, and Nutrition, Stanford University, Stanford, CA.

    Liver allografts are known to be well tolerated and indeed, some recipients of liver allografts retain stable graft function in the absence of immunosuppression. The…
  • 2015 American Transplant Congress

    Repurposing Jak/STAT Signaling Inhibition to Enhance Costimulation Blockade and Promote Transplant Acceptance

    G. Raimondi, S. Khalifian, D. Miller, B. Oh, G. Furtmueller, M. Fryer, W. Lee, G. Brandacher.

    Plastic and Reconstructive Surgery, Johns Hopkins University, Baltimore.

    PURPOSE: Transplant tolerance induction through conventional costimulation blockade (CoB) remains an elusive goal. Recent evidence suggests that inflammatory cytokines contribute to the activation of alloreactive…
  • 2015 American Transplant Congress

    Rational Development of Alloantigen Specific Regulatory T Cell Therapy Requires Insight Into Longevity of Alloimmune Pathways

    J. Ali, M. Negus, E. Bolton, J. Bradley, G. Pettigrew.

    University of Cambridge, Cambridge, United Kingdom.

    IntroductionWe have recently demonstrated that indirect-pathway responses against different alloantigens differ in their strength and longevity; specifically, that indirect responses against MHC class I alloantigen…
  • 2015 American Transplant Congress

    IL-2/IL-2 Ab Complex Leads to Long-Term Tolerance in a Treg Dependent DST Model of Skin Allograft Transplantation in Which DST and Timing of the Antibody Complex Are Crucial

    G. Zhang,1 Y. Wang,1 M. Hu,1 A. Sawyer,1 J. Zhou,1 S. Grey,2 S. Alexander.1

    1Children's Hospital at Westmead, Sydney, Australia; 2Garvan Institute, Sydney, Australia.

    Background: In vivo Treg expansion using IL2 complexed with anti-IL2 antibody has been demonstrated to be effective in the induction of long-term acceptance of islet…
  • 2015 American Transplant Congress

    Donor Specific Expansion of Regulatory T-Cells Was Associated With Allograft Tolerance Induced By Transient Mixed Chimerism in Nonhuman Primates

    K. Hotta, A. Aoyama, T. Ohura, M. Tonsho, Y. Yamada, J. Allan, J. Madsen, B. Cosimi, G. Benichou, T. Kawai.

    Transplant Center, Massachusetts General Hospital, Boston, MA.

    Background: We have previously reported successful induction of solid organ allograft tolerance in nonhuman primates (NHP) via a mixed chimerism approach. Since these recipients achieved…
  • 2015 American Transplant Congress

    Tolerance to Graft A-Antigens Following ABO-Incompatible Heart Transplantation (HTx) in a Blood Group A-Transgenic Mouse Model

    B. Motyka,1 K. Labonte,1 F. Rahman,1 J. Pearcey,1 K. Tao,1 M. Mengel,1 B. Sis,1 P. Cowan,2 L. West.1

    1Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada; 2Immunology Research Centre, St Vincent's Hospital, Melbourne, Australia.

    Purpose: ABOi HTx can be performed safely in infants when ABO antibody (Ab) levels are low or absent. Following ABOi HTx, immune tolerance develops to…
  • 2015 American Transplant Congress

    Regulatory Tolerance Across a Full MHC Barrier Is More Robust Than Tolerance Across a Class I MHC Disparity Alone

    M. Madariaga, S. Michel, G. La Muraglia II, M. O'Neil, W. Orent, V. Villani, M. Sekijima, E. Farkash, R. Colvin, J. Allan, K. Yamada, J. Madsen, D. Sachs.

    Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

    Background: We previously demonstrated that tolerance of hearts and/or kidneys achieved across a class I MHC mismatch with 12 days of CyA can be abrogated…
  • « Previous Page
  • 1
  • …
  • 1357
  • 1358
  • 1359
  • 1360
  • 1361
  • …
  • 1683
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences